KRAS-Mutant MSS Metastatic Colorectal Cancer (2L)
Data readoutStock, pipeline and biotech catalyst intelligence
Clinical portfolio
| Asset | Indication | Stage | Milestone | Signals ? |
|---|---|---|---|---|
| Pelareorep + Bevacizumab + FOLFIRI (Oncolytic Virus) | KRAS-Mutant MSS Metastatic Colorectal Cancer (2L) | Phase 2 | Dec 31, 2026 | — |
Upcoming milestones
KRAS-Mutant MSS Metastatic Colorectal Cancer (2L)
Data readoutCompany profile
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (GI) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in San Diego, California.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.